News

COMPANY UPDATES

2014: Artax Biopharma obtains the approval for Phase I clinical trial.

2014: Phase Ia for tolerability and safety of leading compound.

2015: Phase Ib; food effect, safety and tolerability of leading compound started.

 

PRESS RELEASE & PUBLICATIONS

2015: Artax Biopharma Raises $10M Series B to fund Phase Ib-IIa clinical trials for AX-024, a novel oral treatment; and to further develop its pipeline of preclinical candidates.?

2017: First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Science Translational Medicine 21 Dec 2016: Vol. 8, Issue 370, pp. 370ra184.